10 Healthcare and Software Stocks to Buy According to Michel Massoud’s Melqart Asset Management
In this article, we take a look at the 10 healthcare and software stocks to buy according to Michel Massoud’s Melqart Asset Management.
Constellation Pharmaceuticals Inc (CNST)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Magnetar Capital Alec Litowitz And Ross Laser | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% | ||
| 3. | 0 | $0 | 0% | ||
| 4. | Balyasny Asset Management Dmitry Balyasny | 0 | $0 | 0% | |
| 5. | Pentwater Capital Management Matthew Halbower | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $23.15 | 5,539 | $128,227.85 | 6,051,376 | 2020-03-20 | Filing | |
| $22.38 | 36,135 | $808,701.30 | 6,045,837 | 2020-03-19 | Filing | |
| $23.15 | 5,539 | $128,227.85 | 6,051,376 | 2020-03-20 | Filing | |
| $22.38 | 36,135 | $808,701.30 | 6,045,837 | 2020-03-19 | Filing | |
| $34.50 | 400,000 | $13,800,000.00 | 5,742,765 | 2019-12-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $37.60 | 6,260 | $235,373.50 | 0 | 2021-02-22 | Filing | |
| $37.71 | 4,010 | $151,217.90 | 0 | 2021-02-19 | Filing | |
| $36.95 | 10,000 | $369,503.00 | 99,155 | 2021-02-17 | Filing | |
| $36.95 | 10,000 | $369,503.00 | 99,155 | 2021-02-17 | Filing | |
| $37.58 | 1,100 | $41,343.06 | 0 | 2021-02-18 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% | |
| 3. | 0 | $0 | 0% | |
| 4. | 0 | $0 | 0% | |
| 5. | 0 | $0 | 0% |
News See All
11 Best Pharma and Biotech Stocks to Buy According to Jim Simons' Euclidean Capital
In this article, we will discuss the 11 best pharma and biotech stocks to buy according to Jim Simons' Euclidean Capital.
Should I Avoid Constellation Pharmaceuticals, Inc. (CNST)?
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors...
Is CNST Stock A Buy or Sell?
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their positions at the end of every quarter.
Was The Smart Money Wrong About Constellation Pharmaceuticals, Inc. (CNST)?
While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to get cautious...
Hedge Funds Are Betting On Constellation Pharmaceuticals, Inc. (CNST)
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors...
Did Hedge Funds Make The Right Call On Constellation Pharmaceuticals, Inc. (CNST) ?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Is Constellation Pharmaceuticals, Inc. (CNST) A Good Stock To Buy?
In this article we will take a look at whether hedge funds think Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) is a good investment right now.
Was The Smart Money Right About Constellation Pharmaceuticals (CNST)?
Hedge funds don't get the respect they used to get. Nowadays investors prefer passive funds over actively managed funds.
Hedge Funds Have Never Been More Bullish On Constellation Pharmaceuticals, Inc. (CNST)
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts, usually don't make them change their opinion towards ...
Billionaire Hedge Funds
